Adam Lankowski

Adam Lankowski is a commercialization manager at Bristol Myers Squibb, where he oversees the development and market introduction of innovative therapies, including the oral medication Mazigdomide, which is being studied for its potential to improve treatment outcomes for patients with multiple myeloma.